Portuguese pharmaceutical company Bial has heard that an expert panel tasked with investigating the cause of a clinical trial death in France three months ago has found that the volunteer died “as a result of the drug’s toxicity”.
In a report published earlier this week by the French agency for the Safety of Health Products, experts said the incident “seemed clearly linked” to the “molecule” being tested , rather than possible mistakes in how the drug was administered, or its dosage.